A citation-based method for searching scientific literature

Sarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, Wendy Xiong, Li Xu, Rosa Mostorino, Vivek Subbiah, Nizar Tannir, Siqing Fu, Aung Naing, Filip Janku, Daniel D Karp, Shreyaskumar Patel, Najat C Daw, David Hong, Funda Meric-Bernstam, Ralph Zinner. Onco Targets Ther 2021
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model.
Hiromichi Oshiro, Yasunori Tome, Kentaro Miyake, Takashi Higuchi, Norihiko Sugisawa, Fuminori Kanaya, Kotaro Nishida, Robert M Hoffman. Sci Rep 2021
2
50

A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatinum-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
Kentaro Igarashi, Kei Kawaguchi, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Takashi Higuchi, Yuta Taniguchi, Hirotaka Yonezawa, Yoshihiro Araki,[...]. Cancer Genomics Proteomics 2020
2
50

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
Zhichao Tian, Xiaohui Niu, Weitao Yao. Front Oncol 2020
16
50

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes.
Yoko S DeRose, Guoying Wang, Yi-Chun Lin, Philip S Bernard, Saundra S Buys, Mark T W Ebbert, Rachel Factor, Cindy Matsen, Brett A Milash, Edward Nelson,[...]. Nat Med 2011
603
50


Update on Osteosarcoma.
Rebekah Belayneh, Mitchell S Fourman, Sumail Bhogal, Kurt R Weiss. Curr Oncol Rep 2021
5
50

PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
Takashi Higuchi, Jun Yamamoto, Norihiko Sugisawa, Yoshihiko Tashiro, Hiroto Nishino, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi,[...]. Cancer Genomics Proteomics 2020
7
50

Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Toshimitsu Yamaoka, Sojiro Kusumoto, Koichi Ando, Motoi Ohba, Tohru Ohmori. Int J Mol Sci 2018
82
50

Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Kentaro Miyake, Tasuku Kiyuna, Kei Kawaguchi, Takashi Higuchi, Hiromichi Oshiro, Zhiying Zhang, Sintawat Wangsiricharoen, Sahar Razmjooei, Yunfeng Li, Scott D Nelson,[...]. Cancer Chemother Pharmacol 2019
13
50

Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study.
Thomas Brodowicz, Bernadette Liegl-Atzwanger, Nicolas Penel, Olivier Mir, Jean-Yves Blay, Karl Kashofer, Axel Le Cesne, Emilie Decoupigny, Jennifer Wallet, Rainer Hamacher,[...]. Cancers (Basel) 2020
2
50

Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Norihiko Sugisawa, Takashi Higuchi, Qinghong Han, Chihiro Hozumi, Jun Yamamoto, Yoshihiko Tashiro, Hiroto Nishino, Kei Kawaguchi, Michael Bouvet, Takuya Murata,[...]. Cancer Chemother Pharmacol 2021
2
50

Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model.
Takashi Higuchi, Norihiko Sugisawa, Kentaro Miyake, Hiromichi Oshiro, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Zoey Kline,[...]. Anticancer Res 2019
10
50

Targeted therapy for hepatocellular carcinoma: Challenges and opportunities.
Shuzhen Chen, Qiqi Cao, Wen Wen, Hongyang Wang. Cancer Lett 2019
60
50

Multikinase inhibitors in thyroid cancer: timing of targeted therapy.
Matti L Gild, Venessa H M Tsang, Roderick J Clifton-Bligh, Bruce G Robinson. Nat Rev Endocrinol 2021
8
50

A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer.
K Kiguchi, T Kubota, D Aoki, Y Udagawa, S Yamanouchi, M Saga, A Amemiya, F X Sun, S Nozawa, A R Moossa,[...]. Clin Exp Metastasis 1998
46
50

Sorafenib: key lessons from over 10 years of experience.
Bernard Escudier, Francis Worden, Masatoshi Kudo. Expert Rev Anticancer Ther 2019
32
50

Systematic Review of Recurrent Osteosarcoma Systemic Therapy.
Ioanna Gazouli, Anastasios Kyriazoglou, Ioannis Kotsantis, Maria Anastasiou, Anastasios Pantazopoulos, Maria Prevezanou, Ioannis Chatzidakis, Georgios Kavourakis, Panagiota Economopoulou, Vasileios Kontogeorgakos,[...]. Cancers (Basel) 2021
9
50

Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors.
Philipp Ivanyi, Hendrik Eggers, Mareike Hornig, Bernd Kasper, Klaus Heissner, Hans-Georg Kopp, Martha Kirstein, Arnold Ganser, Viktor Grünwald. Mol Clin Oncol 2020
1
100

Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium.
Douglas J Harrison, Jonathan D Gill, Michael E Roth, Wendong Zhang, Beverly Teicher, Stephen Erickson, Greg Gatto, Raushan T Kurmasheva, Peter J Houghton, Malcolm A Smith,[...]. Pediatr Blood Cancer 2020
3
50

Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma.
Takashi Higuchi, Hiromichi Oshiro, Kentaro Miyake, Norihiko Sugisawa, Qinghong Han, Yuying Tan, Junho Park, Zhiying Zhang, Sahar Razmjooei, Norio Yamamoto,[...]. Anticancer Res 2019
12
50

Regorafenib.
Thomas J Ettrich, Thomas Seufferlein. Recent Results Cancer Res 2018
35
50

Multikinase Inhibitor Treatment in Thyroid Cancer.
Ole Vincent Ancker, Marcus Krüger, Markus Wehland, Manfred Infanger, Daniela Grimm. Int J Mol Sci 2019
18
50


Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model.
Takashi Higuchi, Norihiko Sugisawa, Kentaro Miyake, Hiromichi Oshiro, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Sant P Chawla,[...]. Anticancer Res 2019
9
50


Usefulness of Implementing Comprehensive Pharmaceutical Care for Metastatic Renal Cell Carcinoma Outpatients Treated with Pazopanib.
Maki Todo, Suguru Shirotake, Koshiro Nishimoto, Yota Yasumizu, Gou Kaneko, Hideyuki Kondo, Takashi Okabe, Hideki Makabe, Masafumi Oyama. Anticancer Res 2019
8
50

Pazopanib for the treatment of soft-tissue sarcoma.
Pierre Heudel, Philippe Cassier, Olfa Derbel, Armelle Dufresne, Pierre Meeus, Philippe Thiesse, Dominique Ranchère-Vince, Jean Yves Blay, Isabelle Ray-Coquard. Clin Pharmacol 2012
17
50

A novel patient-derived orthotopic xenograft (PDOX) mouse model of highly-aggressive liver metastasis for identification of candidate effective drug-combinations.
Zhiying Zhang, Kaiwen Hu, Kentaro Miyake, Tasuku Kiyuna, Hiromichi Oshiro, Sintawat Wangsiricharoen, Kei Kawaguchi, Takashi Higuchi, Sahar Razmjooei, Masuyo Miyake,[...]. Sci Rep 2020
2
50

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation.
Misato Ogata, Yukimasa Hatachi, Takatsugu Ogata, Hironaga Satake, Yukihiro Imai, Hisateru Yasui. Intern Med 2019
8
50

Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
A S Mansfield, S J Murphy, F R Harris, S I Robinson, R S Marks, S H Johnson, J B Smadbeck, G C Halling, E S Yi, D Wigle,[...]. Ann Oncol 2016
36
50

ALK-positive inflammatory myofibroblastic tumor of the abdomen with widespread microscopic multifocality.
Luisa Lorenzi, Marta Cigognetti, Daniela Medicina, Vilma Pellegrini, Piera Balzarini, Renzo Cestari, Fabio Facchetti. Int J Surg Pathol 2014
10
50

TNS1-ALK Fusion in a Recurrent, Metastatic Uterine Mesenchymal Tumor Originally Diagnosed as Leiomyosarcoma.
Jessica Lee, Arun Singh, Siraj M Ali, Douglas I Lin, Samuel J Klempner. Acta Med Acad 2019
3
50

Efficacy and Resistance of ALK Inhibitors in Two Inflammatory Myofibroblastic Tumor Patients with ALK Fusions Assessed by Whole Exome and RNA Sequencing.
Chenlu Zhang, Zhiming Wang, Rongyuan Zhuang, Xi Guo, Yi Feng, Feng Shen, Wenshuai Liu, Yong Zhang, Hanxing Tong, Wending Sun,[...]. Onco Targets Ther 2020
2
50

Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literature.
Qiuyu Liu, Yunzhen Kan, Yuewu Zhao, Hui He, Lingfei Kong. Int J Clin Exp Pathol 2015
13
50

A Pilot Prospective Study of Refractory Solid Tumor Patients for NGS-Based Targeted Anticancer Therapy.
Young Mi Seol, Chae Hwa Kwon, So Jeong Lee, Seon Jin Lee, Yuri Choi, Young Jin Choi, Hyojeong Kim, Do Youn Park. Transl Oncol 2019
7
50


Crizotinib in ALK+ inflammatory myofibroblastic tumors-Current experience and future perspectives.
Till-Martin Theilen, Jan Soerensen, Konrad Bochennek, Martina Becker, Dirk Schwabe, Udo Rolle, Thomas Klingebiel, Thomas Lehrnbecher. Pediatr Blood Cancer 2018
26
50

A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
Shiro Kimbara, Koji Takeda, Hiroko Fukushima, Toru Inoue, Hideaki Okada, Yumi Shibata, Utae Katsushima, Asuka Tsuya, Shinya Tokunaga, Haruko Daga,[...]. Jpn J Clin Oncol 2014
29
50

GPC1-ALK: A novel ALK fusion in a patient with pulmonary sarcomatoid carcinoma.
Lei Xiong, Xiao Li, Dongsheng Chen, Si Li, Liguo Luo. Lung Cancer 2021
1
100

Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition.
Sophie Reinhart, Yasmin Trachsel, Christine Fritz, Ulrich Wagner, Beata Bode-Lesniewska, Hubert John, Miklos Pless. Urology 2020
3
50

Haploinsufficiency of RanBP2 is neuroprotective against light-elicited and age-dependent degeneration of photoreceptor neurons.
K-in Cho, H Yi, A Yeh, N Tserentsoodol, L Cuadrado, K Searle, Y Hao, P A Ferreira. Cell Death Differ 2009
24
50

ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor.
Sebastian Y F Michels, Andreas H Scheel, Thomas Wündisch, Johannes M Heuckmann, Roopika Menon, Michael Puesken, Carsten Kobe, Helen Pasternack, Carina Heydt, Matthias Scheffler,[...]. NPJ Precis Oncol 2017
12
50

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
James E Butrynski, David R D'Adamo, Jason L Hornick, Paola Dal Cin, Cristina R Antonescu, Suresh C Jhanwar, Marc Ladanyi, Marzia Capelletti, Scott J Rodig, Nikhil Ramaiya,[...]. N Engl J Med 2010
520
50

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors.
Yuki Takeyasu, Hitomi S Okuma, Yuki Kojima, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Tatsunori Shimoi, Emi Noguchi, Ayumu Arakawa, Taisuke Mori,[...]. JCO Precis Oncol 2021
2
50

Epithelioid Inflammatory Myofibroblastic Sarcoma of the Ovary With RANB2-ALK Fusion: Report of a Case.
Hong Fang, Carrie L Langstraat, Daniel W Visscher, Andrew L Folpe, J Kenneth Schoolmeester. Int J Gynecol Pathol 2018
8
50

Complete and Repeated Response of a Metastatic ALK-rearranged Inflammatory Myofibroblastic Tumor to Crizotinib in a Teenage Girl.
Jérémie Gaudichon, Corinne Jeanne-Pasquier, Marianna Deparis, Alexis Veyssière, Maxime Heyndrickx, Odile Minckes, Daniel Orbach. J Pediatr Hematol Oncol 2016
17
50

Crizotinib-associated Renal Cyst Formation in a Pediatric Patient With ALK+ Epithelioid Inflammatory Myofibroblastic Sarcoma.
Alexei Kopelevich, Sarah A Holzman, Justin La, Hollie A Lai, Lilibeth Torno, Heidi A Stephany. Urology 2021
1
100

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
50

A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib.
Weifeng Liu, Qianqian Duan, Lihua Gong, Yongkun Yang, Zhen Huang, Hao Guo, Xiaohui Niu. Invest New Drugs 2021
2
50

Epithelioid inflammatory myofibroblastic sarcoma responsive to surgery and an ALK inhibitor in a patient with panhypopituitarism.
Kotomi Kurihara-Hosokawa, Isao Kawasaki, Anna Tamai, Yoko Yoshida, Yosuke Yakushiji, Hiroki Ueno, Mariko Fukumoto, Hiroko Fukushima, Takeshi Inoue, Masayuki Hosoi. Intern Med 2014
12
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.